Chemotherapy is the treatment of choice in metastatic stage of small-cell lung cancer
(SCLC). Radiation therapy, surgery and other forms of therapy are only included in special …

Opinion statement Small cell lung cancer (SCLC) is an aggressive type of lung cancer
characterized by rapid growth and early metastasis. It is chemosensitive and radiosensitive …

In a case study-based workshop, physicians were asked to discuss various aspects of
patient management in small cell lung cancer (SCLC). For first-line chemotherapy, most …

The overall treatment results in metastatic small-cell lung cancer have not been changed in
the last decades. The prognosis of the disease is still poor with median survival times of less …

The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC
is nearly universally smoking-related and is very sensitive to both chemotherapy and …

There were approximately 42,000 new cases of small cell lung cancer (SCLC) in 2002.
Despite its initial sensitivity to chemotherapy, only 10% of all SCLC patients will have …

Small-cell lung cancer is an aggressive tumor associated with high rates of regional or
distant metastases at diagnosis. Although highly chemosensitive to agents given in the first …

Introduction: Small cell lung cancer (SCLC) will account for 25,000 to 32,000 new lung
cancer cases in the USA in 2010. Current treatment approaches include platinum-based …

Combination chemotherapy is the current strategy of choice for treatment of small cell lung
cancer (SCLC). Platinum containing combination regimens are superior to non-platinum …

Small cell lung cancer accounts for 13–15% of all lung cancer worldwide. There has been a
decrease in the number of cases, with no clear explanation, except probably to changing in …